A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020
Andreas Obermair, Jim Nicklin, Val Gebski, Sandra C Hayes, Nicholas Graves, Linda Mileshkin, Ming Yin Lin, Phillip Beale, Eva Baxter, Kristy Robledo, Carlos Salomon, George B Hanna, Monika Janda
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | BMJ PUBLISHING GROUP | Published : 2021
BACKGROUND: Sentinel node biopsy is a surgical technique to explore lymph nodes for surgical staging of endometrial cancer, which has replaced full retroperitoneal lymph node dissection. However, the effectiveness of sentinel node biopsy, its value to patients, and potential harms compared with no-node dissection have never been shown in a randomized trial. PRIMARY OBJECTIVES: Stage 1 will test recovery from surgery. Stage 2 will compare disease-free survival at 4.5 years between patients randomized to sentinel node biopsy versus no retroperitoneal node dissection. STUDY HYPOTHESIS: The primary hypothesis for stage 1 is that treatment with sentinel node biopsy will not cause detriment to pat..View full abstract
This study was funded by Royal Brisbane and Women's Hospital (RBWH) Foundation, NHMRC Investigator Grant, Cherish Women's Cancer Foundation, Wesley Medical Research Foundation.